3.2.1. SF-36
INFLAMMATORY BOWEL DISEASE
At week 10, patients who had received filgotinib 200 mg had greater LS mean increases from induction baseline in SF-36 PCS and MCS scores than those who had received placebo [Proportions of patients achieving the MCID in SF-36, EQ-5D, WPAI and IBDQ total scores in Induction Studies A and B at week 10 and in the Maintenance Study at week 58
CI, confidence interval; EQ-5D, EuroQol 5-dimension; EQ-5D-5L, EuroQol 5-dimension 5-level; HRQoL, health-related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; MCID, minimal clinically important difference; SF-36, 36-Item Short-Form Survey; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment questionnaire.Change in SF-36 PCS [A, B], SF-36 MCS [C, D], EQ-5D VAS [E, F], EQ-5D-5L UK utility [G, H] and IBDQ total [I, J] scores in Induction Studies A and B at week 10. Error bars indicate 95% CIs. CI, confidence interval; EQ-5D, EuroQol 5-dimension; EQ-5D-5L, EuroQol 5-dimension 5-level; IBDQ, Inflammatory Bowel Disease Questionnaire; LS, least-squares; MCS, mental component summary; PCS, physical component.At week 58, patients in the filgotinib 200 mg group had LS mean increases from maintenance baseline in SF-36 PCS and MCS scores, whereas patients in the respective placebo group had LS mean decreases in the same measures [Change in SF-36 PCS [A], SF-36 MCS [B], EQ-5D VAS [C], EQ-5D-5L UK utility [D] and IBDQ total [E] scores in the Maintenance Study at week 58. Error bars indicate 95% CIs. CI, confidence interval; EQ-5D, EuroQol 5-dimension; EQ-5D-5L, EuroQol 5-dimension 5-level; IBDQ, Inflammatory Bowel Disease Questionnaire; LS, least-squares; MCS, mental component summary; PCS, physical component summary; SF-36, 36-Item Short-Form Survey; VAS, visual analogue scale.In a further analysis, we assessed restoration of HRQoL as measured using SF-36 scores. Among patients with an SF-36 PCS or MCS score of <40 at induction baseline, a greater proportion of those treated with filgotinib 200 mg than those treated with placebo achieved restoration of SF-36-defined HRQoL [SF-36 PCS or MCS score ≥40] by week 10 in the biologic-naïve and biologic-experienced populations [all 